今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 688062 | 迈威生物 | -5.53 | 7.46 | -6948.29 | | 002007 | 华兰生物 | -1.41 | 1.37 | -6643.00 | | 300558 | 贝达药业 | -3.26 | 1.78 | -5441.57 | | 300122 | 智飞生物 | -0.25 | 1.08 | -3370.31 | | 300683 | 海特生物 | -7.15 | 11.21 | -3346.26 | | 688166 | 博瑞医药 | -1.31 | 1.41 | -3278.54 | | 000513 | 丽珠集团 | -0.56 | 0.84 | -2709.13 | | 300723 | 一品红 | -5.07 | 2.71 | -2659.12 | | 688266 | 泽璟制药 | -3.41 | 0.88 | -2615.23 | | 603707 | 健友股份 | -4.00 ...

资料显示，贝达药业股份有限公司位于浙江省杭州市临平区经济技术开发区兴中路355号,香港铜锣湾希 慎道33号利园1期19楼1919室，成立日期2003年1月7日，上市日期2016年11月7日，公司主营业务涉及药 品的研发、生产和销售。主营业务收入构成为：药品销售99.10%，其他(补充)0.90%。 贝达药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：眼科概念、抗癌治癌、 抗癌药物、创新药、生物医药等。 10月23日，贝达药业盘中下跌2.03%，截至09:47，报57.08元/股，成交3774.79万元，换手率0.16%，总 市值240.15亿元。 资金流向方面，主力资金净流出442.88万元，特大单买入0.00元，占比0.00%，卖出218.89万元，占比 5.80%；大单买入502.80万元，占比13.32%，卖出726.80万元，占比19.25%。 贝达药业今年以来股价涨6.23%，近5个交易日跌2.94%，近20日跌16.83%，近60日跌8.99%。 分红方面，贝达药业A股上市后累计派现6.69亿元。近三年，累计派现1.84亿元。 机构持仓方面，截止2025年6月30日，贝达药业十 ...

Group 1 - On October 22, 2023, Benda Pharmaceutical conducted a block trade of 95,800 shares, with a transaction amount of 4.4844 million yuan, accounting for 1.28% of the total trading volume for the day [1][2] - The transaction price was 46.81 yuan per share, which represents a discount of 19.65% compared to the market closing price of 58.26 yuan [1][2]

2025 年 10 月 20 日 证券研究报告 行业周报 行业评级： | 报告期：2025.10.9-2025.10.19 | | | --- | --- | | 投资评级 | 看好 | | 评级变动 | 维持评级 | 分析师： huchenxi@gwgsc.com 执业证书编号：S0200518090001 联系电话：010-68085205 分析师 魏钰琪 weiyuqi@gwgsc.com 执业证书编号：S0200525060001 联系电话：010-68099389 公司地址：北京市丰台区凤凰嘴街 2 号院 1 号楼中国长城资产大厦 16 层 医药生物行业双周报 2025 年第 21 期总第 144 期 政策规范临床研究路径 重磅创新成果集中亮相 2025ESMO 大会 行业回顾 本报告期医药生物行业指数跌幅为 3.65%，在申万 31 个一级行业中 位居第 21，跑输沪深 300 指数（-2.73%）。从子行业来看，中药、 线下药店涨幅居前，涨幅分别为 1.90%、0.88%；医疗研发外包、医 疗设备跌幅居前，跌幅分别为 11.40%、5.54%。 行业走势： 估值方面，截至 2025 年 10 月 ...

坚定看好创新主线，积极把握 Q3 业绩 医药生物 证券研究报告/行业定期报告 2025 年 10 月 19 日 | 分析师：祝嘉琦 | | --- | | 执业证书编号：S0740519040001 | | Email：zhujq@zts.com.cn | | 分析师：于佳喜 | | 执业证书编号：S0740523080002 | | Email：yujx03@zts.com.cn | | 基本状况 | | 上市公司数 | 515 | | --- | --- | | 行业总市值(亿元) | 73,158.98 | | 行业流通市值(亿元) | 66,630.42 | 免赛道蓄势待发》2025-10-13 瞻》2025-10-10 绩改善》2025-10-07 | 增持（维持） 评级： | | | 重点公司基本状况 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 简称 | 股价 | | | EPS | | | | | ...

Index Performance - The CSI A500 Index decreased by 3.31% this week, closing at 5392.97 points on October 17 [5] - The average daily trading volume for the week was 8521.04 billion yuan, reflecting a 22.20% decrease compared to the previous week [5] Top Performers - The top ten gainers in the CSI A500 index included: 1. Shanghai Pudong Development Bank (600000.SH) with a gain of 12.50% 2. Agricultural Bank of China (601288.SH) with a gain of 11.57% 3. Huatian Technology (002185.SZ) with a gain of 10.02% 4. Shanghai Jahwa United Co., Ltd. (600315.SH) with a gain of 9.42% 5. Hainan Airport (600515.SH) with a gain of 8.96% 6. Shaanxi Coal and Chemical Industry (601225.SH) with a gain of 8.61% 7. Jiangsu Bank (600919.SH) with a gain of 8.60% 8. Tongwei Co., Ltd. (600438.SH) with a gain of 8.31% 9. Air China (601111.SH) with a gain of 7.63% 10. China Pacific Insurance (601319.SH) with a gain of 7.32% [2] Bottom Performers - The top ten losers in the CSI A500 index included: 1. Shengquan Group (605589.SH) with a loss of 18.04% 2. Wentai Technology (600745.SH) with a loss of 17.17% 3. Betta Pharmaceuticals (300558.SZ) with a loss of 16.98% 4. Leo Group (002131.SZ) with a loss of 16.55% 5. Jinlang Technology (300763.SZ) with a loss of 15.40% 6. Tongfu Microelectronics (002156.SZ) with a loss of 14.98% 7. Yake Technology (002409.SZ) with a loss of 14.35% 8. Lens Technology (300433.SZ) with a loss of 14.26% 9. Zhongding Sealing Parts (000887.SZ) with a loss of 13.99% 10. Robot Technology (300757.SZ) with a loss of 13.95% [2] Fund Performance - All 40 CSI A500 ETFs experienced declines, with notable drops in Huatai-PB's CSI A500 Enhanced ETF and Guolian's A500 Enhanced ETF, both falling over 4% [5] - The total scale of the CSI A500 ETFs fell below 200 billion yuan, with Huatai-PB's fund at 249.03 billion yuan, Guotai's at 226.56 billion yuan, and E Fund's at 221.29 billion yuan [5] Market Insights - Pacific Securities research team suggests a balanced allocation towards low-position sectors, particularly banks and insurance with dividend protection attributes, as well as coal and agriculture sectors benefiting from domestic demand recovery [6] - Guohai Securities research team indicates that uncertainties from trade frictions may lead to a rotation in market styles, with a shift from overvalued growth sectors to undervalued sectors [6]

Core Viewpoint - Boda Pharmaceutical's stock has experienced a decline recently, with a notable drop of 15.08% over the past five trading days, despite a year-to-date increase of 7.26% [2]. Group 1: Stock Performance - As of October 17, Boda Pharmaceutical's stock price was 57.63 CNY per share, with a market capitalization of 24.247 billion CNY [1]. - The stock has seen a decline of 17.67% over the past 20 days and 5.71% over the past 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Boda Pharmaceutical reported a revenue of 1.731 billion CNY, representing a year-on-year growth of 15.37%. However, the net profit attributable to shareholders decreased by 37.53% to 140 million CNY [2]. Group 3: Shareholder Information - As of September 30, the number of shareholders for Boda Pharmaceutical was 29,500, a decrease of 7.99% from the previous period. The average number of circulating shares per shareholder increased by 8.68% to 14,198 shares [2]. - The company has distributed a total of 669 million CNY in dividends since its A-share listing, with 184 million CNY distributed over the past three years [3]. Group 4: Institutional Holdings - As of June 30, 2025, notable institutional shareholders include E Fund's ChiNext ETF, which holds 6.3678 million shares, a decrease of 107,600 shares from the previous period. New institutional shareholders include China Europe Medical Health Mixed A, holding 4.3513 million shares, and Southern CSI 500 ETF, holding 3.7474 million shares [3].

证券日报网讯贝达药业（300558）10月16日在互动平台回答投资者提问时表示，奥布替尼是一款BTK抑 制剂，公司会关注该领域发展，目前尚无可公示的新药项目立项。人工智能在靶点发现、耐药机制识别 及真实世界研究等方面显现了巨大的潜力，公司会积极引入AI辅助技术，进一步提升研发效率，从而 赋能药物研发与临床研究。 ...

Core Viewpoint - On October 16, 2023, Benda Pharmaceutical conducted a block trade involving 58,000 shares at a transaction price of 46.31 yuan, which represents a discount of 21.25% compared to the market closing price of 58.81 yuan [1][2]. Summary by Category Transaction Details - The block trade on October 16 involved a total transaction amount of 2.686 million yuan, accounting for 0.59% of the total trading volume for that day [1][2]. - The buyer was Guangfa Securities Co., Ltd., and the seller was Founder Securities Co., Ltd. [2]. Price Comparison - The transaction price of 46.31 yuan is significantly lower than the market closing price of 58.81 yuan, indicating a substantial discount of 21.25% [1].

每经AI快讯，有投资者在投资者互动平台提问：公司是否有研发奥布替尼等药物？公司有组建AI团队 辅助研发项目吗？ 贝达药业（300558.SZ）10月16日在投资者互动平台表示，奥布替尼是一款BTK抑制剂，公司会关注该 领域发展，目前尚无可公示的新药项目立项。人工智能在靶点发现、耐药机制识别及真实世界研究等方 面显现了巨大的潜力，公司会积极引入AI辅助技术，进一步提升研发效率，从而赋能药物研发与临床 研究。 （文章来源：每日经济新闻） ...